Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CymaBay Therapeutics, Inc.CBAY · Entity 92768 | Director | February 07, 2019 | February 08, 2019 |
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Director | June 18, 2025 | June 20, 2025 |
| Enliven Therapeutics, Inc.IMRA · Entity 4024 | Director | June 02, 2022 | June 03, 2022 |
| ReShape Weightloss Inc.ETRM · Entity 137993 | Director | May 25, 2017 | May 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CymaBay Therapeutics, Inc.
Report date February 07, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-02-07 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-02-07 · Exercise / conversion · Acquired 2,335 · Balance 2,335 Row 2 · 2019-02-07 · Exercise / conversion · Acquired 9,340 · Balance 11,675 Row 3 · 2019-02-07 · Sale · Disposed 11,675 · Balance 0 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2023-12-22 | Direct | 0 |
Reported balance
After 2019-02-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-07 · Exercise / conversion · Disposed 2,335 · Balance 0 F2: Fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2027-06-27 | Direct | 0 |
Reported balance
After 2019-02-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-07 · Exercise / conversion · Disposed 9,340 · Balance 0 F2: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Fully vested.
Damora Therapeutics, Inc.
Report date June 18, 2025 · Filed June 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2035-06-18 | Direct | 1,440 |
Reported balance
After 2025-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 1,440 · Balance 1,440 F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.
Enliven Therapeutics, Inc.
Report date June 02, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2032-06-01 | Direct | 8,500 |
Reported balance
After 2022-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-02 · Grant · Acquired 8,500 · Balance 8,500 F2: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy entities affiliated with Bay City Capital LLC | 703,380 |
Reported balance
Holding disclosure · report date 2022-06-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 703,380 F1: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an advisor of BCC LLC and a member of GP V and and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an advisor of BCC LLC and a member of GP V and and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein
F2: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.
ReShape Weightloss Inc.
Report date May 25, 2017 · Filed May 31, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 0 |
Reported balance
After 2017-05-25 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-05-25 · Sale · Disposed 4,571 · Balance 0 F2: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired. F1: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range. F3: Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 0 |
Reported balance
After 2017-05-25 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2017-05-25 · Sale · Disposed 97 · Balance 0 F2: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired. F1: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range. F4: Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range.
F2: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired.
F3: Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
F4: Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Epizyme, Inc.
Report date August 12, 2022 · Filed August 16, 2022
Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-12 · Disposition to issuer · Disposed 13,060 · Balance 8,994 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Row 2 · 2022-08-12 · Disposition to issuer · Disposed 8,994 · Balance 0 F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. |
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-08-12 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-08-12 · Disposition to issuer · Disposed 3,380,951 · Balance 0 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. F3: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.
F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.
F3: Represents shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. Bay City Capital Management V LLC ("GP V") is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, "BCC V"). Bay City Capital, LLC ("BCC LLC") is the manager of GP V. The Reporting Person is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2017 Filed Nov 6, 2017 20:45 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 18,000 | $8.66 | $155,880.00 |
DisclosureSEC source: 0001209191-17-059524 · doc4.xml · nonDerivative · entry 3 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.60 to $8.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 20:45 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 9,000 | $2.97 | $26,730.00 |
DisclosureSEC source: 0001209191-17-059524 · doc4.xml · nonDerivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 20:45 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 9,000 | $1.72 | $15,480.00 |
DisclosureSEC source: 0001209191-17-059524 · doc4.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 09:35 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001209191-17-053899 · doc4.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-09-21 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date. The option allows for early exercise by the Reporting Person. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 14:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001042074-17-000016 · primary_doc.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 13:54 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001209191-17-041810 · doc4.xml · derivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option was granted on June 22, 2017, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on June 22, 2018 and, in the event of a change in control of the Company, the vesting will accelerate in full. Read SEC document |
| May 25, 2017 Filed May 26, 2017 15:10 UTC | ReShape Weightloss Inc. ETRM · Entity 137993 | SaleCommon Stock | 97 | $4.85 | $470.45 |
DisclosureSEC source: 0001179110-17-008065 · edgar.xml · nonDerivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote note (2) Disclosed balance after: 0 F6 · price: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range. F2 · ownership.nature: Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein. Read SEC document |
| May 25, 2017 Filed May 26, 2017 15:10 UTC | ReShape Weightloss Inc. ETRM · Entity 137993 | SaleCommon Stock | 4,571 | $4.85 | $22,169.35 |
DisclosureSEC source: 0001179110-17-008065 · edgar.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (1) Disclosed balance after: 0 F6 · price: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range. F1 · ownership.nature: Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein. Read SEC document |
| May 25, 2017 Filed May 31, 2017 15:31 UTC Amendment | ReShape Weightloss Inc. ETRM · Entity 137993 | SaleCommon Stock | 97 | $4.85 | $470.45 |
DisclosureSEC source: 0001179110-17-008246 · edgar.xml · nonDerivative · entry 2 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 F2 · shares: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired. F1 · price: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range. F4 · ownership.nature: Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein. Read SEC document |
| May 25, 2017 Filed May 31, 2017 15:31 UTC Amendment | ReShape Weightloss Inc. ETRM · Entity 137993 | SaleCommon Stock | 4,571 | $4.85 | $22,169.35 |
DisclosureSEC source: 0001179110-17-008246 · edgar.xml · nonDerivative · entry 1 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 F2 · shares: This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired. F1 · price: The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:45 UTC | ReShape Weightloss Inc. ETRM · Entity 137993 | GrantDirector Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-17-009584 · doc4.xml · derivative · entry 13 GOLDFISCHER CARL · CIK 0001110780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-02-08 F5 · derivative.exercise_date: 25% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month over the three (3) year period measured from the date shown. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.